Morgan Stanley Ab Cellera Biologics Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,792,142 shares of ABCL stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,792,142

Previous 996,927 180.07%

Holding current value

$10.3 Million

Previous $3.42 Million 310.76%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$3.49 - $5.15 $6.27 Million - $9.25 Million	1,795,215 Added 180.07%	2,792,142 $14 Million
Q2 2025 Aug 15, 2025	SELL	$1.93 - $3.8 $567,591 - $1.12 Million	-294,089 Reduced 22.78%	996,927 $3.42 Million
Q1 2025 May 15, 2025	BUY	$2.2 - $3.53 $777,988 - $1.25 Million	353,631 Added 37.73%	1,291,016 $2.88 Million
Q4 2024 Feb 14, 2025	BUY	$2.48 - $3.15 $862,375 - $1.1 Million	347,732 Added 58.97%	937,385 $2.75 Million
Q3 2024 May 14, 2025	BUY	$2.39 - $3.49 $89,679 - $130,955	37,523 Added 6.8%	589,653 $1.53 Million

Q3 2024 Nov 14, 2024	BUY	$2.39 - $3.49 $89,679 - $130,955	37,523 Added 6.8%	589,653 $1.53 Million
Q2 2024 May 14, 2025	SELL	$2.73 - $4.73 $1.05 Million - $1.82 Million	-385,255 Reduced 41.1%	552,130 $1.63 Million
Q2 2024 Oct 17, 2024	BUY	$2.73 - $4.73 $442,235 - $766,217	161,991 Added 41.52%	552,130 $1.63 Million
Q2 2024 Aug 14, 2024	BUY	$2.73 - $4.73 $442,235 - $766,217	161,991 Added 41.52%	552,130 $1.63 Million
Q1 2024 Oct 17, 2024	SELL	$4.29 - $5.97 $694,941 - $967,086	-161,991 Reduced 29.34%	390,139 $1.77 Million
Q1 2024 Aug 16, 2024	BUY	$4.29 - $5.97 $56,838 - $79,096	13,249 Added 3.52%	390,139 $1.77 Million
Q1 2024 May 15, 2024	BUY	$4.29 - $5.97 $56,838 - $79,096	13,249 Added 3.52%	390,139 $1.77 Million
Q4 2023 Aug 16, 2024	SELL	$3.91 - $5.93 $685,188 - $1.04 Million	-175,240 Reduced 31.74%	376,890 $2.15 Million
Q4 2023 Feb 13, 2024	SELL	$3.91 - $5.93 $799,692 - $1.21 Million	-204,525 Reduced 35.18%	376,890 $2.15 Million
Q3 2023 Nov 15, 2023	SELL	$4.6 - $7.95 $2.76 Million - $4.78 Million	-600,731 Reduced 50.82%	581,415 $2.67 Million
Q2 2023 Aug 14, 2023	BUY	$5.66 - $7.59 $1.54 Million - $2.07 Million	272,742 Added 29.99%	1,182,146 $7.64 Million
Q1 2023 May 15, 2023	BUY	$7.31 - $11.18 $2 Million - $3.06 Million	273,870 Added 43.09%	909,404 $6.86 Million
Q4 2022 Feb 14, 2023	SELL	$9.48 - $14.52 $639,672 - $979,751	-67,476 Reduced 9.6%	635,534 $6.44 Million
Q3 2022 Nov 14, 2022	BUY	$9.2 - $13.68 $2.06 Million - $3.06 Million	224,007 Added 46.77%	703,010 $6.95 Million
Q2 2022 Oct 27, 2022	BUY	$5.72 - $10.65 $491,159 - $914,483	85,867 Added 21.84%	479,003 $5.1 Million
Q2 2022 Aug 15, 2022	BUY	$5.72 - $10.65 $491,159 - $914,483	85,867 Added 21.84%	479,003 $5.1 Million
Q1 2022 Oct 27, 2022	SELL	$7.46 - $14.14 $640,567 - $1.21 Million	-85,867 Reduced 17.93%	393,136 $3.83 Million
Q1 2022 May 13, 2022	SELL	$7.46 - $14.14 $804,441 - $1.52 Million	-107,834 Reduced 21.53%	393,136 $3.83 Million
Q4 2021 Feb 14, 2022	SELL	$12.99 - $17.73 $3.05 Million - $4.17 Million	-235,049 Reduced 31.94%	500,970 $7.17 Million
Q3 2021 Nov 15, 2021	BUY	$14.85 - $21.34 $10.9 Million - $15.7 Million	736,019 New	736,019 $14.8 Million

Others Institutions Holding ABCL

# of Institutions

170

Shares Held

110M

Call Options Held

1.26M

Put Options Held

788K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $1.05B
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account